Myval经导管心脏瓣膜系统治疗严重主动脉瓣狭窄-目前的证据和未来的方向。

IF 1.9 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS

Heart International Pub Date : 2020-12-23 eCollection Date: 2020-01-01 DOI:10.17925/HI.2020.14.2.86

Gunasekaran Sengottuvelu, Vijay Kumar, Ashok Seth

{"title":"Myval经导管心脏瓣膜系统治疗严重主动脉瓣狭窄-目前的证据和未来的方向。","authors":"Gunasekaran Sengottuvelu, Vijay Kumar, Ashok Seth","doi":"10.17925/HI.2020.14.2.86","DOIUrl":null,"url":null,"abstract":"Transcatheter aortic valve replacement has revolutionised the treatment of aortic valve disease. The Myval™ device (Meril Life Sciences Pvt. Ltd., Gujarat, India) is a CE-marked, next-generation balloon-expandable transcatheter heart valve, designed for the treatment of severe aortic valve stenosis. This review illustrates the salient technical features of this transcatheter valve, pre-clinical studies and evidence from the first-in-human trial. We also provide a brief overview of planned clinical trials and registries.","PeriodicalId":12836,"journal":{"name":"Heart International","volume":"14 2","pages":"86-91"},"PeriodicalIF":1.9000,"publicationDate":"2020-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9524723/pdf/heart-int-14-86.pdf","citationCount":"4","resultStr":"{\"title\":\"The Myval Transcatheter Heart Valve System for the Treatment of Severe Aortic Stenosis - Current Evidence and Future Directions.\",\"authors\":\"Gunasekaran Sengottuvelu, Vijay Kumar, Ashok Seth\",\"doi\":\"10.17925/HI.2020.14.2.86\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Transcatheter aortic valve replacement has revolutionised the treatment of aortic valve disease. The Myval™ device (Meril Life Sciences Pvt. Ltd., Gujarat, India) is a CE-marked, next-generation balloon-expandable transcatheter heart valve, designed for the treatment of severe aortic valve stenosis. This review illustrates the salient technical features of this transcatheter valve, pre-clinical studies and evidence from the first-in-human trial. We also provide a brief overview of planned clinical trials and registries.\",\"PeriodicalId\":12836,\"journal\":{\"name\":\"Heart International\",\"volume\":\"14 2\",\"pages\":\"86-91\"},\"PeriodicalIF\":1.9000,\"publicationDate\":\"2020-12-23\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9524723/pdf/heart-int-14-86.pdf\",\"citationCount\":\"4\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Heart International\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.17925/HI.2020.14.2.86\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2020/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q3\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Heart International","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.17925/HI.2020.14.2.86","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2020/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 4

摘要

经导管主动脉瓣置换术彻底改变了主动脉瓣疾病的治疗。Myval™装置(Meril Life Sciences Pvt. Ltd.， Gujarat, India)是ce认证的下一代球囊可膨胀经导管心脏瓣膜，专为治疗严重主动脉瓣狭窄而设计。这篇综述阐述了这种经导管瓣膜的突出技术特点、临床前研究和首次人体试验的证据。我们还提供了计划的临床试验和注册的简要概述。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

The Myval Transcatheter Heart Valve System for the Treatment of Severe Aortic Stenosis - Current Evidence and Future Directions.

Transcatheter aortic valve replacement has revolutionised the treatment of aortic valve disease. The Myval™ device (Meril Life Sciences Pvt. Ltd., Gujarat, India) is a CE-marked, next-generation balloon-expandable transcatheter heart valve, designed for the treatment of severe aortic valve stenosis. This review illustrates the salient technical features of this transcatheter valve, pre-clinical studies and evidence from the first-in-human trial. We also provide a brief overview of planned clinical trials and registries.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Heart International Medicine-Cardiology and Cardiovascular Medicine

CiteScore

0.90

自引率

0.00%

发文量

审稿时长

7 weeks